13 June 2023 in ChemBioChem
Artificial intelligence (AI) in the form of deep learning has promise for drug discovery and chemical biology, for example, to predict protein structure and molecular bioactivity, plan organic synthesis, and design moleculesde novo. While most of the deep learning efforts in drug discovery have focused on ligand‐based approaches, structure‐based drug discovery has the potential to tackle unsolved challenges, such as affinity prediction for unexplored protein targets, binding‐mechanism elucidation, and the rationalization of related chemical kinetic properties. Advances in deep‐learning methodologies and the availability of accurate predictions for protein tertiary structure advocate for arenaissancein structure‐based approaches for drug discovery guided by AI. This review summarizes the most prominent algorithmic concepts in structure‐based deep learning for drug discovery, and forecasts opportunities, applications, and challenges ahead.
25 April 2024 in Current Opinion in Structural Biology
Deep learning is becoming increasingly relevant in drug discovery, from de novo design to protein structure prediction and synthesis planning. However, it is often challenged by the small data regimes typical of certain drug discovery tasks. In such scenarios, deep learning approaches-which are notoriously 'data-hungry'-might fail to live up to their promise. Developing novel approaches to leverage the power of deep learning in low-data scenarios is sparking great attention, and future developments are expected to propel the field further. This mini-review provides an overview of recent low-data-learning approaches in drug discovery, analyzing their hurdles and advantages. Finally, we venture to provide a forecast of future research directions in low-data learning for drug discovery.
22 July 2024 in Nature Communications
Generative deep learning is reshaping drug design. Chemical language models (CLMs) – which generate molecules in the form of molecular strings – bear particular promise for this endeavor. Here, we introduce a recent deep learning architecture, termed Structured State Space Sequence (S4) model, into de novo drug design. In addition to its unprecedented performance in various fields, S4 has shown remarkable capabilities to learn the global properties of sequences. This aspect is intriguing in chemical language modeling, where complex molecular properties like bioactivity can ‘emerge’ from separated portions in the molecular string. This observation gives rise to the following question: Can S4 advance chemical language modeling for de novo design? To provide an answer, we systematically benchmark S4 with state-of-the-art CLMs on an array of drug discovery tasks, such as the identification of bioactive compounds, and the design of drug-like molecules and natural products. S4 shows a superior capacity to learn complex molecular properties, while at the same time exploring diverse scaffolds. Finally, when applied prospectively to kinase inhibition, S4 designs eight of out ten molecules that are predicted as highly active by molecular dynamics simulations. Taken together, these findings advocate for the introduction of S4 into chemical language modeling – uncovering its untapped potential in the molecular sciences.
9 July 2025 in Journal of Chemical Information and Modeling
In recent years, generative deep learning has emerged as a transformative approach in drug design, promising to explore the vast chemical space and generate novel molecules with desired biological properties. This perspective examines the challenges and opportunities of applying generative models to drug discovery, focusing on the intricate tasks related to small molecule generation, evaluation, and prioritization. Central to this process is navigating conflicting information from diverse sources─balancing chemical diversity, synthesizability, and bioactivity. We discuss the current state of generative methods, their optimization, and the critical need for robust evaluation protocols. By mapping this evolving landscape, we outline key building blocks, inherent dilemmas, and future directions in the journey to fully harness generative deep learning in the "chemical odyssey" of drug design.
22 November 2020 in Molecular Informatics
16 December 2024 in Digital Discovery
Deep learning offers a plethora of solutions to accelerate drug discovery. Here we discover simple and effective approaches to develop bioactivity prediction models via ‘chemical language’.